News
23 September 2020
Other Diseases
- Research Projects

Through ImmUniverse, EFA is involved in research aiming at improving diagnostic and therapeutic options for patients living with immune-mediated inflammatory diseases, including atopic eczema and ulcerative colitis. In ImmUniverse, EFA brings the perspective and voice of atopic eczema patients.

Setting up a Patient Input Platform

Together with EFCCA (the European Federation of Crohn’s and Ulcerative Colitis Associations), EFA is building an efficient and informed dialogue between researchers and patients, to guide clinicians respond to patients’ needs throughout the project.

EFA and EFCCA are currently establishing a Patient Input Platform composed of atopic dermatitis and ulcerative colitis patients to help ensure a patient-centric approach across the research. The expert patient will advise on clinical research procedures, support the interpretation of research outcomes, and assist in disseminating the results.

Keeping patients informed

EFA is also involved in the Communication Committee that has been created to facilitate project communication and dissemination activities, including  the ImmUniverse’s website. One key feature of the website is the “Patient’s Voice” section, dedicated to atopic eczema and ulcerative colitis patients,.

The ImmUniverse project is funded by the Innovative Medicine Initiative (IMI), a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA) to advance health research and innovation.

More information on the ImmUniverse project can be found here.

Dear Visitor,

for regularly updated information on Covid-19 for allergy and respiratory patients, please consult our Covid-19 resource and information hub.
Stay safe!
The EFA Team